Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer, June 8, 2011 JAMA Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, June 05, 2011

Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer, June 8, 2011 JAMA



Objectives To define characteristics of orphan cancer drugs and their pivotal clinical trials and to compare these with nonorphan drugs.

.......More treated patients had serious adverse events in trials of orphan drugs vs trials of nonorphan drugs (48% vs 36%; odds ratio, 1.72; 95% confidence interval, 1.02-2.92; P = .04).


Conclusion Compared with pivotal trials used to approve nonorphan cancer drugs, pivotal trials for recently approved orphan drugs for cancer were more likely to be smaller and to use nonrandomized, unblinded trial designs and surrogate end points to assess efficacy.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.